We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+4.66%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$70.8M
Cap. Flow
+$67.6M
Cap. Flow %
8.55%
Top 10 Hldgs %
17.24%
Holding
1,106
New
68
Increased
214
Reduced
81
Closed
742

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$92.4M
2
FAF icon
First American
FAF
+$3.54M
3
AEO icon
American Eagle Outfitters
AEO
+$3.46M
4
DHI icon
D.R. Horton
DHI
+$3.39M
5
RVT icon
Royce Value Trust
RVT
+$3.37M

Top Sells

Rank Stock Value
1
INP
iPath ETNs Linked to the MSCI India Total Return Index
INP
+$7.25M
2
AAPL icon
Apple
AAPL
+$5.78M
3
AVGO icon
Broadcom
AVGO
+$4.33M
4
BIDU icon
Baidu
BIDU
+$4.21M
5
WBA
Walgreens Boots Alliance
WBA
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 13.69%
2 Technology 11.98%
3 Consumer Discretionary 11.21%
4 Financials 10.27%
5 Industrials 9.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYAD
326
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$829K 0.1%
+15,182
New +$669K
CLLS
327
Cellectis
CLLS
$285M
$825K 0.1%
+26,597
New +$807K
BLCM
328
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$819K 0.1%
+4,040
New +$723K
MRK icon
329
Merck
MRK
$318B
$813K 0.1%
16,126
-5,256
-25% -$265K
AZN icon
330
AstraZeneca
AZN
$250B
$808K 0.1%
+11,904
New +$780K
CTMX icon
331
CytomX Therapeutics
CTMX
$754M
$804K 0.1%
+38,502
New +$609K
ICLR icon
332
Icon
ICLR
$12.7B
$795K 0.1%
+10,234
New +$731K
BLUE
333
DELISTED
bluebird bio
BLUE
$789K 0.1%
+948
New +$947K
FPRX
334
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$784K 0.1%
+18,884
New +$633K
AGEN
335
Agenus
AGEN
$290M
$778K 0.1%
+8,727
New +$798K
CLDX icon
336
Celldex Therapeutics
CLDX
$3.28B
$775K 0.1%
+3,296
New +$719K
NVS icon
337
Novartis
NVS
$297B
$775K 0.1%
+10,052
New +$799K
IMDZ
338
DELISTED
Immune Design Corp.
IMDZ
$771K 0.1%
+38,384
New +$661K
XNCR icon
339
Xencor
XNCR
$1.55B
$769K 0.1%
+52,598
New +$707K
LUMO
340
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$766K 0.1%
2,340
+1,660
+244% +$540K
INO icon
341
Inovio Pharmaceuticals
INO
$69M
$756K 0.1%
+9,377
New +$747K
CELG
342
DELISTED
Celgene Corp
CELG
$754K 0.1%
6,295
-10,608
-63% -$1.23M
ADXS
343
DELISTED
Advaxis Inc
ADXS
$740K 0.09%
+4,904
New +$842K
MGNX icon
344
MacroGenics
MGNX
$257M
$739K 0.09%
+23,852
New +$725K
JUNO
345
DELISTED
Juno Therapeutics, Inc.
JUNO
$714K 0.09%
+16,249
New +$806K
IOVA icon
346
Iovance Biotherapeutics
IOVA
$2.87B
$711K 0.09%
+92,153
New +$639K
KDNY
347
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$705K 0.09%
+5,009
New +$680K
JPC icon
348
Nuveen Preferred & Income Opportunities Fund
JPC
$2.9B
$685K 0.09%
74,796
-40,793
-35% -$373K
KITE
349
DELISTED
Kite Pharma, Inc.
KITE
$676K 0.09%
+10,972
New +$772K
TCRT icon
350
Alaunos Therapeutics
TCRT
$4.86M
$645K 0.08%
+517
New +$855K
12 13
14
15 16

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
WI
Winder Investment Singapore $4.4B AUM 8.87% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

Vident Investment Advisory's Q4 2015 Portfolio in Review

As of Q4 2015, Vident Investment Advisory held 1,106 positions worth $791M, up 9.8% from $720M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Vident Investment Advisory deployed $67.6M of net new capital in Q4 2015, opening 68 new positions and adding to 214 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 450,105 shares worth $91.8M.

By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 15% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Apple, an estimated $5.78M trimmed.

  • Vident Investment Advisory's largest Q4 2015 buy was State Street SPDR S&P 500 ETF Trust: 450,105 shares worth $91.8M.
  • Vident Investment Advisory added most to D.R. Horton in Q4 2015, an estimated $3.39M increase.
  • Vident Investment Advisory's biggest Q4 2015 reduction was Apple, cutting an estimated $5.78M.
  • Vident Investment Advisory fully exited iPath ETNs Linked to the MSCI India Total Return Index in Q4 2015, selling an estimated $7.25M.
  • Vident Investment Advisory's ten largest holdings make up 17% of its $791M portfolio in Q4 2015.
  • Vident Investment Advisory opened 68 new positions and closed 742 in Q4 2015.
  • Vident Investment Advisory's portfolio value rose 9.8% quarter-over-quarter to $791M.

Based on Vident Investment Advisory's 13F filing for Q4 2015, filed 17 Feb 2016.